Ronald Hunziger
Family · Buffalo, MONPI 1306154711
Payments from drug & device makers
Across 98 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$351
- GSK$187
- Novo Nordisk$150
- AbbVie$136
- Pfizer$113
- Takeda Pharmaceuticals U.S.A., Inc.$94
- plus $344 from 12 others
What the payments were for
- Food & beverage$1,375100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $351 |
| GSK | 18 | $187 |
| Novo Nordisk | 10 | $150 |
| AbbVie | 13 | $136 |
| Pfizer | 6 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $94 |
| Organon | 5 | $61 |
| Astellas Pharma US Inc | 3 | $57 |
| Amgen | 3 | $40 |
| Amarin Pharma, Inc. | 3 | $38 |
| Collegium Pharmaceutical, Inc. | 3 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Abbott | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
How this compares
$1,375 in reported general payments places this provider in the 70th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 59 | $47,932 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $40,374 |
| TrulicityDulaglutide | 38 | $38,811 |
| EliquisApixaban | 44 | $35,110 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $32,045 |
| TradjentaLinagliptin | 26 | $25,743 |
| JanuviaSitagliptin Phosphate | 15 | $20,614 |
| OzempicSemaglutide | 16 | $15,548 |
| XareltoRivaroxaban | 23 | $12,716 |
| Spiriva HandihalerTiotropium Bromide | 18 | $9,403 |
| InvokanaCanagliflozin | 12 | $6,421 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $4,422 |
| VascepaIcosapent Ethyl | 11 | $3,928 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $3,826 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 150 | $3,593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $13 | $73,67685 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $187 | $72,419100 claims |
| Lilly USA, LLCTrulicity | $11 | $38,81138 claims |
| PfizerEliquis | $113 | $35,11044 claims |
| Novo NordiskOzempic | $150 | $15,54816 claims |
| AstraZenecaSymbicort | $351 | $4,42220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,812 family providers in Missouri.
Other family in Buffalo
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.